Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.

Magnetic resonance spectroscopy (MRS) methods have provided valuable information on cancer cell metabolism. In this study, we characterized the 31P-MR spectra of breast cancer cell lines exhibiting differences in hormonal response, estrogen receptors (positive/negative), and metastatic potential. A correlation was made between the cytotoxic effect of antimitotic drugs and changes in cell metabolism pattern. Because most anticancer drugs are more effective on proliferating cells, our study attempted to elucidate the metabolic profile and specific metabolic changes associated with the effect of anticancer drugs on proliferating breast cancer cell lines. Accordingly, for the 31P-MRS experiments, cells were embedded in Matrigel to preserve their proliferation profile and ability to absorb drugs. The MRS studies of untreated cells indicated that the levels of phosphodiesters and uridine diphosphosugar metabolites were significantly higher in estrogen receptor-positive and low metastatic potential cell lines. 31P-MRS observations revealed a correlation between the mode of action of anticancer drugs and the observed changes in cell metabolic profiles. When cells were treated with antimicrotubule drugs (paclitaxel, vincristine, colchicine, nocodazole), but not with methotrexate and doxorubicin, a profound elevation of intracellular glycerophosphorylcholine (GPC) was recorded that was not associated with changes in phospholipid composition of cell membrane. Remarkably, the rate of elevation of intracellular GPC was much faster in cell population synchronized at G2-M compared with the unsynchronized cells. The steady-state level of GPC for paclitaxel-treated cells was reached after approximately 4 h for synchronized cells and after approximately 24 h (approximate duration of one cell cycle) for the unsynchronized ones. These observations may indicate a correlation between microtubule status and cellular phospholipid metabolism. This study demonstrates that 31P-MRS may have diagnostic value for treatment decisions of breast cancer and reveals new aspects of the mechanism of action of antimicrotubule drugs.

[1]  R. Snyderman,et al.  Influence of cytoskeletal assembly on phosphatidylcholine synthesis in intact phagocytic cells , 1980, Cell.

[2]  V. Boyd,et al.  31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. , 1986, Journal of medicinal chemistry.

[3]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[4]  G. Batist,et al.  Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy. , 1986, Cancer research.

[5]  I. Parikh,et al.  Are estrogen receptors cytoplasmic or nuclear? Some immunocytochemical and biochemical studies. , 1987, Journal of steroid biochemistry.

[6]  J. S. Cohen,et al.  Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. , 1987, The Journal of biological chemistry.

[7]  J. S. Cohen,et al.  31P‐NMR spectroscopy of human cancer cells proliferating in a basement membrane gel , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  T. Glonek,et al.  High resolution 31P NMR of extracted phospholipids. , 1988, Journal of lipid research.

[9]  M. Neeman,et al.  Early estrogen-induced metabolic changes and their inhibition by actinomycin D and cycloheximide in human breast cancer cells: 31P and 13C NMR studies. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Neeman,et al.  Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. , 1989, Cancer research.

[11]  J. Vion-Dury,et al.  Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy. , 1989, Biochimie.

[12]  R. Clarke,et al.  The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer. , 1989, The Journal of endocrinology.

[13]  P. B. Barker,et al.  31P NMR of mammalian cells encapsulated in alginate gels utilizing a new phosphate‐free perfusion medium , 1990, NMR in biomedicine.

[14]  D. Leibfritz,et al.  Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. , 1990, Biochimica et biophysica acta.

[15]  M. Lippman,et al.  Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. , 1990, The Journal of biological chemistry.

[16]  G. Zugmaier,et al.  Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study. , 1990, Cancer research.

[17]  G. Navon,et al.  Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. , 1990, Cancer research.

[18]  R. Clarke,et al.  The process of malignant progression in human breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. Bendel,et al.  In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF7 human breast cancer implanted in nude mice. , 1991, Cancer communications.

[20]  H. Degani,et al.  Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study , 1991, Cancer.

[21]  C. Surridge,et al.  Phosphatidylinositol inhibits microtubule assembly by binding to microtubule-associated protein 2 at a single, specific, high-affinity site. , 1992, Biochemistry.

[22]  J. Ruíz-Cabello,et al.  Phospholipid metabolites as indicators of cancer cell function , 1992, NMR in biomedicine.

[23]  P. Devaux,et al.  Phospholipid transmembrane domains and lateral diffusion in fibroblasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Harris,et al.  Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. , 1993, European journal of cancer.

[25]  C. Leslie,et al.  Regulation of cytosolic phospholipase A2 phosphorylation and eicosanoid production by colony-stimulating factor 1. , 1994, The Journal of biological chemistry.

[26]  F. Leonessa,et al.  Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. , 1994, Cancer research.

[27]  H. Kleinman,et al.  Enhancement of tumor growth by basement membrane: modulation of growth and angiogenesis by laminin-derived synthetic peptides. , 1994, Cancer treatment and research.

[28]  M. Valverde,et al.  Novel plasma membrane action of estrogen and antiestrogens revealed by their regulation of a large conductance chloride channel , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  A. Hanauske,et al.  Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. , 1994, European journal of cancer.

[30]  M. Jordan,et al.  Pharmacological probes of microtubule function , 1994 .

[31]  J. Ruíz-Cabello,et al.  A history of biological applications of NMR spectroscopy , 1995 .

[32]  C. Zupke,et al.  Nuclear magnetic resonance analysis of cell metabolism. , 1995, Current opinion in biotechnology.

[33]  E. Rowinsky,et al.  Paclitaxel in cancer treatment , 1995 .

[34]  H. Degani,et al.  Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.

[35]  W. Hull,et al.  31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. , 1996, Anticancer research.

[36]  V. Jordan,et al.  MCF-7: the first hormone-responsive breast cancer cell line. , 1997, Cancer research.

[37]  K. Titani,et al.  Specific Binding of Acidic Phospholipids to Microtubule-associated Protein MAP1B Regulates Its Interaction with Tubulin* , 1997, The Journal of Biological Chemistry.

[38]  Jimmy D Bell,et al.  Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours , 1998, NMR in biomedicine.

[39]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[40]  S. Jackowski,et al.  Cellular Responses to Excess Phospholipid* , 1999, The Journal of Biological Chemistry.

[41]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[42]  R. Gillies,et al.  Nm23‐transfected MDA‐mB‐435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: A 31P nuclear magnetic resonance study in vivo and in vitro , 1999, Magnetic resonance in medicine.

[43]  S. Kish,et al.  Phosphatidylcholine and phosphatidylethanolamine metabolites may regulate brain phospholipid catabolism via inhibition of lysophospholipase activity , 1999, Brain Research.